KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Notes Payables: 2024

Historic Notes Payables for Esperion Therapeutics (ESPR) over the last 1 years, with Dec 2024 value amounting to $54.6 million.

  • Esperion Therapeutics' Notes Payables was N/A to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.9 million, marking a year-over-year change of. This contributed to the annual value of $54.6 million for FY2024, which is N/A change from last year.
  • As of FY2024, Esperion Therapeutics' Notes Payables stood at $54.6 million.
  • Esperion Therapeutics' Notes Payables' 5-year high stood at $54.6 million during FY2024, with a 5-year trough of $54.6 million in FY2024.
  • Its 1-year average for Notes Payables is $54.6 million, with a median of $54.6 million in 2024.